Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.0899
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fsd Pharma Inc Cl B
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
May 31, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
May 29, 2024
Via
Investor Brand Network
MiningNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
May 29, 2024
Via
Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency
May 28, 2024
Via
Investor Brand Network
HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024
May 20, 2024
FSD Pharma just reported results for the first quarter of 2024.
Via
InvestorPlace
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
May 28, 2024
Via
ACCESSWIRE
FSD Pharma Provides Corporate Update
May 24, 2024
Via
ACCESSWIRE
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
May 16, 2024
Via
ACCESSWIRE
TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
May 07, 2024
Via
Investor Brand Network
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 07, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
April 30, 2024
Via
Investor Brand Network
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
April 30, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Celly Nu, Six+One Collaboration to Launch unbuzzd(TM)
April 25, 2024
Via
Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 25, 2024
Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!
Via
InvestorPlace
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
April 25, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)
April 22, 2024
Via
Investor Brand Network
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
April 22, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline
April 17, 2024
Via
Investor Brand Network
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
April 17, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Update on Celly Nu Investment
April 15, 2024
Via
Investor Brand Network
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
April 15, 2024
Via
ACCESSWIRE
FSD Pharma Announces Filing of Year-End 2023 Results
April 01, 2024
Via
ACCESSWIRE
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study
March 27, 2024
Via
Investor Brand Network
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
March 27, 2024
Via
ACCESSWIRE
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
Via
Benzinga
FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market
March 14, 2024
Via
AB Newswire
FSD Pharma’s Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here’s Why
March 12, 2024
Via
AB Newswire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial
March 11, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.